Etravirine is an effective and well-tolerated recently approved non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV type-1-infected patients with previous antiretroviral treatment experience. Considering the importance of combining antiretrovirals for their optimal use in treating HIV, a number of drug-drug interactions with etravirine and other antiretrovirals have been evaluated. Etravirine is a weak inducer of cytochrome P450 (CYP)3A and a weak inhibitor of CYP2C9/CYP2C19 and P-glycoprotein, and although etravirine is metabolized by the CYP enzyme system, the extent of clinically relevant interactions with other antiretrovirals is limited. Etravirine can be combined with all currently available nucleoside/nucleotide reverse transcriptase inhibitors without dose adjustments, but not with other NNRTIs. Available data indicate that etravirine can be coadministered with most of the currently available ritonavir-boosted HIV protease inhibitors. Coadministration with tipranavir/ritonavir or unboosted HIV protease inhibitors is not recommended because of clinically relevant changes in exposure to etravirine or the coadministered HIV protease inhibitor, respectively. Etravirine can be coadministered with the integrase inhibitors elvitegravir/ritonavir or raltegravir, and with the fusion inhibitor enfuvirtide, without dose adjustments. Dose adjustment of the C-C chemokine receptor type-5 antagonist maraviroc is required, with the type of adjustment depending on whether a boosted HIV protease inhibitor is included in the regimen. In conclusion, etravirine can be combined with most antiretrovirals, with no clinically meaningful effect on drug exposure or safety/tolerability profiles.
Etravirine is an effective and well-tolerated recently approved non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV type-1-infected patients with previous antiretroviral treatment experience. Considering the importance of combining antiretrovirals for their optimal use in treating HIV, a number of drug-drug interactions with etravirine and other antiretrovirals have been evaluated. Etravirine is a weak inducer of cytochrome P450 (CYP)3A and a weak inhibitor of CYP2C9/CYP2C19 and P-glycoprotein, and although etravirine is metabolized by the CYP enzyme system, the extent of clinically relevant interactions with other antiretrovirals is limited. Etravirine can be combined with all currently available nucleoside/nucleotide reverse transcriptase inhibitors without dose adjustments, but not with other NNRTIs. Available data indicate that etravirine can be coadministered with most of the currently available ritonavir-boosted HIV protease inhibitors. Coadministration with tipranavir/ritonavir or unboosted HIV protease inhibitors is not recommended because of clinically relevant changes in exposure to etravirine or the coadministered HIV protease inhibitor, respectively. Etravirine can be coadministered with the integrase inhibitors elvitegravir/ritonavir or raltegravir, and with the fusion inhibitor enfuvirtide, without dose adjustments. Dose adjustment of the C-C chemokine receptor type-5 antagonist maraviroc is required, with the type of adjustment depending on whether a boosted HIV protease inhibitor is included in the regimen. In conclusion, etravirine can be combined with most antiretrovirals, with no clinically meaningful effect on drug exposure or safety/tolerability profiles.
Knowledge of the often complex interactions amongst antiretroviral drugs and their clinical implications is important to maintain antiretroviral efficacy and avoid toxicity [1] . Interactions are likely to occur when agents that are metabolized by the cytochrome P450 (CYP) enzyme system are administered in combination with agents that inhibit and/or induce CYP. HIV protease inhibitors, and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized through this system. In addition to being CYP substrates, these drugs might also be inhibitors and/or inducers of CYP enzymes. The occurrence of interactions has often led to recommendations that certain combinations be avoided, or that adjustment of the dose(s) is necessary [2, 3] .
Etravirine is a recently approved NNRTI with activity against both wild-type and NNRTI-resistant HIV type-1 (HIV-1). Etravirine has a high genetic barrier to the development of resistance and maintains activity despite common NNRTI mutations [4] . Etravirine 200 mg twice daily provided superior virological suppression compared with placebo, when either was given with a background regimen including darunavir/ ritonavir, in two Phase III trials (DUET-1 and DUET-2) [5, 6] . At week 96, 57% versus 36% of etravirine-and placebo-treated patients, respectively, achieved viral load <50 copies/ml (P<0.0001; intent-to-treat, timeto-loss of virological response) in a pooled analysis of both trials [7] . Except for rash (incidences of which were mostly mild-to-moderate and resolved with continued therapy), etravirine generally had a comparable safety and tolerability profile to placebo. With broader use of etravirine, severe cutaneous and hypersensitivity reactions, including Stevens-Johnson Introduction syndrome and toxic epidermal necrolysis have been rarely reported. Because these reactions can be lifethreatening, clinical guidance requires immediate discontinuation of etravirine. No clear relationship between the efficacy or safety of etravirine and pharmacokinetics has been observed [8] .
The importance of interactions between antiretrovirals has led to a comprehensive research programme designed to assess how etravirine interacts with other commonly used antiretrovirals. This review provides an overview of the drug interaction profile of etravirine, based on studies performed with other antiretrovirals to date (Table 1 and Table 2 ).
Clinical pharmacology of etravirine
As with other drugs, the potential for etravirine to be involved in clinically important drug interactions is dependent on a variety of factors, including the characteristics of its absorption, disposition metabolism and elimination.
Etravirine should be taken following a meal to enhance its oral bioavailability. Compared with administration with food, etravirine exposure is approximately half when administered in a fasted state [9] . Although etravirine is extensively bound to albumin (99.6%) and α 1 -acid glycoprotein (94.5%), protein binding displacement is expected to have only transient pharmacological consequences that are of little clinical relevance [10] . Renal elimination of etravirine is minimal (1.2% of the dose administered) [11] ; therefore, competition with other drugs that are eliminated via renal active transport mechanisms is unlikely.
Etravirine is metabolized by CYP3A, CYP2C9 and CYP2C19, followed by glucuronidation of the metabolites by uridine diphosphate glucuronosyl transferase (UDPGT); therefore, coadministration of etravirine with drugs that induce or inhibit CYP3A, CYP2C9 or CYP2C19 might lead to increased or decreased clearance of etravirine, respectively, and thus alter etravirine plasma concentrations.
Although no clinically relevant effects of etravirine on CYP1A2 or CYP2D6 have been demonstrated, etravirine has been shown to be an inducer of CYP3A and an inhibitor of CYP2C9 and CYP2C19 [12] . Etravirine is also an inhibitor of P-glycoprotein [13] ; therefore, coadministration of etravirine with drugs primarily metabolized by CYP3A could result in reduced plasma concentrations of these drugs, potentially leading to a loss of therapeutic effect. Coadministration with drugs metabolized by CYP2C9 or CYP2C19, or transported by P-glycoprotein might result in increased plasma concentrations of such drugs, potentially prolonging their therapeutic effects or affecting their adverse event profiles [14, 15] .
Effect of dose and formulation on interaction potential
Several pharmaceutical formulations of etravirine were produced during clinical development. The commercially available 100 mg tablet is based on a spray-drying manufacturing process and provides higher oral bioavailability than the previous formulation (200 mg tablets), which was used in Phase II trials. The spray-dried formulation, when dosed 200 mg twice daily (four 100 mg tablets daily), results in a substantially reduced pill burden but comparable exposure to that obtained with the formulation used in the Phase II trials (eight 200 mg tablets daily) [13] . After selection of the spray-dried formulation, two drug-drug interaction studies conducted with the Phase II formulation were repeated in order to determine whether a change in formulation would alter interactions. The results indicated that whether etravirine was administered as the commercial formulation or the Phase II formulation, the effects of darunavir/ritonavir or tenofovir disoproxil fumarate on etravirine pharmacokinetics were similar. Also, the effects of etravirine on the pharmacokinetics of darunavir or tenofovir were similar, irrespective of the formulation of etravirine used [14] .
Potential interactions of etravirine with nucleoside/nucleotide reverse transcriptase inhibitors

Didanosine
Didanosine is primarily excreted by the kidney [16] . The potential for etravirine to interact with didanosine at steady-state was investigated in an open-label, crossover trial enrolling 16 healthy adults who received entericcoated didanosine 400 mg once daily for 16 days with etravirine 800 mg twice daily (Phase II formulation) added for 8 days [17] . Didanosine was administered in a fasted state and etravirine was administered with food 1.5 h after didanosine. No clinically significant effect on didanosine or etravirine pharmacokinetic parameters was seen, although the etravirine maximum plasma concentration (C max ) was slightly (16%) increased during coadministration (Table 1 and Table 2 ). No Grade 3 or 4 adverse events, or serious adverse events were reported.
Enteric-coated didanosine is recommended to be taken on an empty stomach as food moderately decreases its exposure (by 20-25%) [18] ; however, no decrease in efficacy was observed in studies of entericcoated didanosine when administered with food [19] [20] [21] . Coadministration of didanosine and etravirine simultaneously with food has not been evaluated.
Tenofovir disoproxil fumarate
Tenofovir is primarily excreted by the kidney and the oral prodrug, tenofovir disoproxil fumarate, is a P-glycoprotein m Trough concentration. ARV, antiretroviral; AUC 12 h or last , area under the plasma concentrationtime curve over 12 h or the last measurable plasma concentration; C max , maximum plasma concentration; C min , minimum plasma concentration; ND, no data; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a Studies were open-label, crossover investigations, unless otherwise stated. b In combination with etravirine versus alone; no effect =1.00. c Healthy volunteers, unless otherwise stated. d Antiretroviral (ARV) drug pharmacokinetic changes. e Drugs for which no dose adjustment of the coadministered drug is necessary when given with etravirine. f The European Medicines Agency label recommends that dose adjustments of fosamprenavir using the oral solution might be required. US and Canada label recommendation is to not coadminister atazanavir and etravirine. g US and Canada label recommends coadministration with etravirine with caution based on the findings from an older drug interaction trial conducted with the soft-gel formulation of lopinavir/ritonavir. h Tibotec Pharmaceuticals. i Drugs for which dose adjustments of the coadministered drug might be necessary when given with etravirine. j Compared with maraviroc 150 mg twice daily. k Drugs for which coadministration with etravirine is not recommended. l Trough concentration. AUC 12 h, 24 h or last , area under the plasma concentration-time curve over 12 h, 24 h or the last measurable plasma concentration; CI, confidence interval; C max , maximum plasma concentration; C min , minimum plasma concentration; ND, no data; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. [62] with darunavir/ritonavir) Darunavir/ritonavir 600/100 mg twice daily (Table 2) was not considered clinically relevant [23] . There was no substantial increase in the number, type or severity of adverse events when etravirine was combined with tenofovir disoproxil fumarate compared with administration alone. The increase in tenofovir exposure might be because of inhibition of intestinal P-glycoprotein by etravirine.
In the Phase III trials, coadministration of etravirine with tenofovir disoproxil fumarate and darunavir/ritonavir was associated with a 26% decrease in etravirine AUC 12 h [24] . The mechanism by which tenofovir reduces etravirine plasma concentrations is unknown; however, virological response in patients receiving etravirine with tenofovir disoproxil fumarate did not differ from that of patients receiving etravirine without tenofovir disoproxil fumarate [23] .
Other nucleoside/nucleotide reverse transcriptase inhibitors
Because nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) other than abacavir are primarily excreted via the kidneys and therefore have a different elimination pathway than etravirine, clinically relevant interactions are not expected. Abacavir is extensively metabolized by UDPGT and alcohol dehydrogenase, enzymes that are not affected by etravirine. The potential for etravirine to interact with N(t)RTIs, such as zidovudine, emtricitabine, stavudine, lamivudine or abacavir, has not been studied.
Recommendations for coadministration of etravirine and nucleoside/nucleotide reverse transcriptase inhibitors
All N(t)RTIs can be combined with etravirine. No dose adjustments are necessary for either drug.
Potential interactions of etravirine with other non-nucleoside reverse transcriptase inhibitors
Efavirenz and nevirapine are potent CYP3A and CYP2B6 inducers [25] . The pharmacokinetics of singledose etravirine were evaluated in two groups of healthy volunteers before and after 14 days of treatment with either efavirenz 600 mg once daily (n=12) or nevirapine 200 mg once daily, increasing to twice daily dosing after 7 days (n=7). In comparison with etravirine alone, coadministration resulted in decreased etravirine exposure of 41% with efavirenz and 55% with nevirapine (Table 1 ) [26] . The effect of single-dose etravirine on the pharmacokinetics of efavirenz or nevirapine was not determined.
The interaction between etravirine and delavirdine has not been studied. Delavirdine is an inhibitor of CYP3A and might potentially increase the exposure of etravirine.
Recommendations for coadministration of etravirine and other non-nucleoside reverse transcriptase inhibitors
It is not recommended to coadminister etravirine with other NNRTIs. One reason is the observed interaction of etravirine with efavirenz and nevirapine, which might result in loss of therapeutic effect. In addition, the 2NN study found an increase in adverse events when efavirenz and nevirapine were combined, compared with administration of each agent alone, and this was not accompanied by increased efficacy, suggesting that a combination of NNRTIs does not provide an added clinical benefit [27] . As etravirine has a higher genetic barrier to the development of resistance than the first-generation NNRTIs, the addition of an NNRTI to a regimen containing etravirine is not expected to improve clinical efficacy.
Potential interactions of etravirine with HIV protease inhibitors
Atazanavir
Atazanavir is metabolized by CYP3A and inhibits CYP3A, CYP2C8, CYP2C19 and UDPGT1A1 in vitro [28] . An open-label, crossover study in 32 healthy volunteers assessed the potential interaction of etravirine with unboosted and boosted atazanavir. Participants received etravirine 800 mg twice daily (Phase II formulation) for 14 days with atazanavir 400 mg once daily or atazanavir/ritonavir 300/100 mg once daily from days 8 to 14. In comparison with etravirine alone, coadministration of atazanavir or atazanavir/ritonavir increased etravirine AUC 12 h by 50% and 30%, respectively (Table 1 ) [29] . Etravirine reduced atazanavir AUC 24 h by 17% in participants who received unboosted atazanavir and by 14% in those who received atazanavir/ritonavir (Table 2) , possibly because of induction of CYP3A by etravirine. The decrease in atazanavir C min in those who received unboosted atazanavir with etravirine administration was 47% and consequently, unboosted atazanavir should not be coadministered with etravirine.
The decrease in atazanavir C min in patients who received boosted atazanavir was 38% (90% confidence interval [CI] 0.55-0.71; Table 2 ); this is comparable to the decrease described when atazanavir/ritonavir was coadministered with tenofovir disoproxil fumarate (least squares mean ratio 0.77, 90% CI 0.54-1.10) [30] . No loss of efficacy was observed with atazanavir/ ritonavir/tenofovir disoproxil fumarate compared with lopinavir/ritonavir/tenofovir disoproxil fumarate [31] ; therefore, the decrease in atazanavir C min seen when this antiretroviral is combined with etravirine is also not expected to be clinically relevant. Furthermore, several clinical trials evaluating the pharmacokinetics of atazanavir (with or without ritonavir), either prospectively or as part of a therapeutic drug monitoring programme, have not established an association between the pharmacokinetics of atazanavir and its antiviral activity. Instead, these trials have determined that the number of atazanavir resistance-associated mutations or the genotypic inhibitory quotient (the number of mutations divided by the C min ) are better predictors of antiviral efficacy than pharmacokinetics [32] [33] [34] [35] [36] .
The pharmacokinetics of atazanavir, when combined with etravirine in HIV-infected patients, as well as efficacy and safety, are being further evaluated in an ongoing trial (TEACH; clinicaltrials.gov identifier NCT00896051).
Darunavir
Darunavir is a CYP3A substrate and inhibitor [37] . The potential for drug interactions with darunavir/ ritonavir was evaluated in two panels of 16 healthy volunteers in a randomized, open-label, crossover trial consisting of two treatment sessions separated by a washout period of at least 14 days. Darunavir/ritonavir 600/100 mg twice daily was administered for 15 days with etravirine 100 or 200 mg twice daily (Phase III formulation) added for the last 7 days in Panel I or II, respectively, and with an additional morning dose on day 16 [38] . The reference treatment was etravirine 100 mg twice daily for 7 days, with an additional dose on day 8. With etravirine 100 mg twice daily, etravirine AUC 12 h was decreased by 37% when coadministered with darunavir/ritonavir (Table 1) , with similar decreases in etravirine C max and C min (32% and 49%, respectively) [38] . When darunavir/ritonavir was given with etravirine 200 mg twice daily, etravirine exposure was increased by 80% relative to the 100 mg twice daily alone dose; C max and C min were also increased, by 81% and 67%, respectively (Table 1) , reflecting the combined effect of the interaction and the higher dose of etravirine. Concomitant administration of etravirine 100 mg twice daily or 200 mg twice daily and darunavir/ritonavir had no clinically significant effect on the pharmacokinetic parameters of darunavir ( Table 2) .
The Phase III studies DUET-1 and DUET-2 have shown that the combination of darunavir/ritonavir 600/100 mg twice daily and etravirine 200 mg twice daily is efficacious and well-tolerated [5] [6] [7] 39] .
The interaction between darunavir/ritonavir and etravirine was less apparent when both drugs were given in a once daily regimen and in the presence of tenofovir disoproxil fumarate. The steady-state pharmacokinetics of etravirine 400 mg once daily (Phase III formulation) with tenofovir disoproxil fumarate and emtricitabine were assessed in antiretroviral-naive HIV-infected volunteers without and with darunavir/ritonavir 800/100 mg once daily. The least squares mean ratios (90% CI) for etravirine coadministered with darunavir/ritonavir relative to etravirine for C max , C min and AUC 24 h were 1.03 (0.93-1.13), 0.96 (0.83-1.10) and 0.99 (0.89-1.10), respectively [40] . In this regimen, etravirine concentrations might be decreased in both treatments (etravirine in combination with tenofovir disoproxil fumarate and emtricitabine, with and without darunavir/ritonavir) because of the presence of tenofovir, with no apparent additional effect of darunavir/ritonavir on etravirine. In addition, it is known that a dose-effect relationship exists regarding the interaction between etravirine and ritonavir; therefore, administering ritonavir at a dose of 100 mg per day, as opposed to 200 mg per day, might have resulted in a smaller effect on plasma etravirine concentrations.
Fosamprenavir
Amprenavir, administered as the prodrug fosamprenavir, is a CYP3A substrate, inducer and inhibitor, as well as a P-glycoprotein substrate [41] . The influence of etravirine on the pharmacokinetics of amprenavir and ritonavir was evaluated in eight patients with HIV-1 infection who were receiving treatment with fosamprenavir/ritonavir 700/100 mg twice daily [42] . When coadministered with fosamprenavir/ritonavir, etravirine AUC 12 h was within the range observed in historical controls [42] . Amprenavir AUC 12 h , C max and C min parameters all showed significant increases (range 62% to 77%; Table 2 ) [42] , potentially because of P-glycoprotein inhibition by etravirine. Despite the increase in amprenavir exposure, the combination of etravirine with fosamprenavir/ritonavir was generally well-tolerated in this short-term study. The increase in amprenavir AUC 12 h (69%) is similar in magnitude to the results of an investigation on the steady-state pharmacokinetic effects of high-dose fosamprenavir, in which an increase of 54% in amprenavir AUC 12 h was observed when fosamprenavir was dosed 1,400/100 mg twice daily relative to 700/100 mg twice daily in healthy volunteers. The efficacy and safety of fosamprenavir 1,400/100 mg twice daily in HIV-infected patients was evaluated in the TRIAD trial. After 24 weeks, fosamprenavir/ritonavir 1,400/100 mg twice daily was not virologically superior to fosamprenavir/ritonavir 700/100 mg twice daily; the most common drug-related adverse event (Grade 2-4) reported in the trial was diarrhoea, which occurred at a greater frequency in the high-dose group relative to the standard-dose group (12% versus 4%, respectively). Plasma amprenavir trough concentrations were approximately 49% higher in the high-dose fosamprenavir group compared with the standard-dose group [43] .
When coadministered with etravirine, dose adjustments of fosamprenavir (with the oral solution) might be necessary to minimize amprenavir side effects.
Indinavir
Indinavir is a CYP3A substrate and inhibitor, as well as a UDPGT inhibitor [44] . The interaction potential of etravirine with indinavir was evaluated in 12 healthy volunteers who received indinavir 800 mg three times daily on days 1 and 2 and a single 800 mg morning dose on day 3. After a washout period of 1 day, all volunteers received etravirine for 13 days, with indinavir 800 mg three times daily added for days 9-13 and both with an additional morning dose on day 14 [26] . In comparison with etravirine alone, concomitant administration of etravirine and indinavir increased etravirine AUC 12 h by 51% (Table 1) , most probably as a result of inhibition of CYP3A and/or UDPGT by indinavir. Conversely, etravirine decreased indinavir AUC 12 h by 46% (Table 2) , probably via induction of CYP3A [26] . As a result, coadministration of etravirine with indinavir is not recommended. At present, no clinical data is available on the combination of etravirine with boosted indinavir.
Lopinavir
Lopinavir/ritonavir is an intestinal and hepatic CYP3A inhibitor and CYP1A1, CYP2C9 and CYP2C19 inducer [45] . The potential of etravirine to interact with lopinavir/ritonavir has been evaluated in two trials. The first trial was an open-label, parallel group trial that evaluated the combination of etravirine with the soft-gel formulation of lopinavir/ritonavir. Compared with etravirine alone, combined administration with lopinavir/ritonavir increased etravirine AUC 12 h by 17% (Table 1) [46] . Adding etravirine did not significantly alter the steady-state pharmacokinetics of either lopinavir or ritonavir; AUC 12 h values were decreased by 20% and 9%, respectively [46] .
A more recent trial evaluated the potential of etravirine to interact with the melt extrusion formulation of lopinavir/ritonavir [47] . In this open-label, crossover trial, 16 volunteers received etravirine 200 mg twice daily (Phase III formulation) for 8 days. After a 14 day washout, lopinavir/ritonavir 400/100 mg twice daily was administered for 16 days, with etravirine 200 mg twice daily being coadministered on days 8-16. Coadministering etravirine with lopinavir/ritonavir melt extrusion formulation resulted in a 30-45% decrease in etravirine pharmacokinetics (Table 1) , which is similar to the decrease observed when etravirine and darunavir/ritonavir are combined (Table 1) . Lopinavir pharmacokinetics decreased by 13-20% (Table 2) ; however, the decrease in lopinavir is not considered clinically relevant.
Nelfinavir
The interaction between nelfinavir and etravirine has not been established. Nelfinavir is metabolized by CYP3A and CYP2C19 [48] , thus alterations in nelfinavir exposure might occur when etravirine is coadministered with nelfinavir.
Ritonavir
Ritonavir is metabolized by CYP3A and, to a lesser extent, CYP2D6, and is itself a potent CYP3A inhibitor as well as an inducer of CYP1A2, CYP2B6, CYP2C and UDPGT. Ritonavir is also a P-glycoprotein substrate and can acutely inhibit P-glycoprotein; however, it induces P-glycoprotein after chronic use [49] . In addition, the commercial preparation of ritonavir contains the surfactant polyoxyl 35 castor oil, which is a putative P-glycoprotein inhibitor [50] . The potential for ritonavir to interact with etravirine is therefore complicated and can involve one or more pathways. The interaction between high-dose ritonavir and etravirine was evaluated in 11 healthy men. Participants were administered a single dose of etravirine before and on day 4 of an escalating-dose ritonavir treatment regimen (300 mg twice daily, increasing progressively to 600 mg twice daily by day 4). In comparison with etravirine alone, coadministration with ritonavir decreased etravirine area under the curve over the last measurable plasma concentration (AUC last ) by 46% (Table 1) , most probably via induction of the CYP2C isozymes [26] . A single dose of ritonavir (100-400 mg) did not affect the exposure of single-dose etravirine (Tibotec Pharmaceuticals, unpublished data), suggesting potent inhibition of CYP3A alone does not affect etravirine pharmacokinetics, possibly because other pathways are also involved in its metabolism. Coadministration of highdose ritonavir with etravirine is not recommended.
Saquinavir
Saquinavir is primarily metabolized by CYP3A and is a P-glycoprotein substrate. Saquinavir/ritonavir was found to reduce etravirine exposure by 33% (Table 1 ; Tibotec Pharmaceuticals, unpublished data). The magnitude of the decrease is consistent with the effects observed when etravirine is coadministered with darunavir/ritonavir and was therefore not considered clinically relevant. The influence of etravirine on the pharmacokinetics of unboosted saquinavir was evaluated in 12 healthy volunteers who received single doses of saquinavir (hardgel formulation) 1,200 mg before and after 14 days of treatment with etravirine. In comparison with saquinavir alone, combined administration with etravirine reduced saquinavir AUC last by 52% and C max by 46%, probably as a result of induction of CYP3A by etravirine [26] . However, addition of low-dose ritonavir (100 mg twice daily) to saquinavir (administered as 1,000 mg twice daily of the soft-gel formulation) and etravirine counteracted this effect, such that exposure to saquinavir was unchanged by etravirine (5% decrease in AUC 12 h ) although saquinavir C min was decreased by 20% ( Table 2 ). The decrease in saquinavir C min is not likely to have a clinically relevant effect on virological response as no association between boosted saquinavir pharmacokinetics and virological response has been established [51] [52] [53] .
Tipranavir
Tipranavir is a substrate, inducer and inhibitor of CYP3A, and is also a P-glycoprotein substrate, a weak P-glycoprotein inhibitor and a potent P-glycoprotein inducer. Coadministration of tipranavir/ritonavir with other agents metabolized by CYP3A might alter the plasma concentrations of either agent and affect their therapeutic and adverse events profiles. With regard to coadministration of tipranavir/ritonavir with agents that induce CYP3A and/or P-glycoprotein, tipranavir concentration might be reduced and its therapeutic effects compromised. Similarly, coadministration with agents that inhibit P-glycoprotein might lead to an increase in tipranavir plasma concentrations, potentially leading to increased toxicity [54] .
The potential drug-drug interaction between tipranavir/ritonavir and etravirine was investigated in healthy volunteers in an open-label, crossover trial. A total of 24 participants received tipranavir/ritonavir 500/200 mg twice daily for 16 days with etravirine 800 mg twice daily (Phase II formulation) added for 8 of these days [55] . In comparison with etravirine alone, coadministration of tipranavir/ritonavir reduced etravirine AUC 12 h by 76% (Table 1 ) [55] . An interaction of similar magnitude is seen when tipranavir/ ritonavir was combined with boosted HIV protease inhibitors [56] . Conversely, tipranavir and ritonavir AUC 12 h were increased when combined with etravirine (by 18% [ Table 2 ] and 23%, respectively) [55] . Tipranavir should not be coadministered with etravirine.
Lopinavir/saquinavir/ritonavir
Lopinavir/saquinavir/ritonavir is sometimes used as a dual-boosted HIV protease inhibitor regimen [57] . To evaluate whether etravirine produces a relevant interaction with this regimen, 15 patients with HIV-1 infection receiving lopinavir soft-gel capsule/saquinavir/ritonavir 400-533/800-1,000/100-133 mg (all administered twice daily) with two or more N(t)RTIs, were given etravirine 800 mg twice daily (Phase II formulation) for 14 days [57] . Decreases of 11-24% were observed in HIV protease inhibitor plasma concentrations and were considered unlikely to be clinically significant. The pharmacokinetics of etravirine were comparable to historical controls [57] .
Summary of interaction of etravirine with HIV protease inhibitors
The effect of HIV protease inhibitors on etravirine exposure varied widely between different agents, from a 50% increase with unboosted atazanavir to a 76% decrease with tipranavir/ritonavir. These differences are probably related to the HIV protease inhibitors, having varying effects on CYP isozymes responsible for etravirine metabolism, as well as the influence of ritonavir dose. When ritonavir is dosed at 100 mg once daily alone (single-dose), no inhibitory effects on etravirine metabolism were observed. However, when ritonavir is dosed at 100 mg once daily with atazanavir (multiple-dose), some induction is noted, in combination with inhibition caused by atazanavir itself -the increase in etravirine exposure in the presence of atazanavir/ritonavir is smaller than that when given with unboosted atazanavir (30% versus 50%) despite the substantially higher systemic exposure to atazanavir in the former case [29] . Multiple-dose coadministration of darunavir/ritonavir 800/100 mg once daily resulted in no appreciable effect on etravirine pharmacokinetics, further suggesting the limited interaction potential of ritonavir when dosed 100 mg once daily.
When ritonavir is dosed 100 mg twice daily, the net effect is CYP induction, as darunavir/ritonavir, lopinavir/ritonavir (melt extrusion formulation) and saquinavir/ritonavir all reduce etravirine AUC 12 h to a similar extent (33-36%). Higher doses of ritonavir (that is, 200 mg twice daily when coadministered with tipranavir 500 mg twice daily) and full-dose ritonavir (600 mg twice daily) decrease etravirine AUC 12 h further (76% and 46%, respectively), although an additional effect of tipranavir on etravirine cannot be ruled out.
Recommendations for coadministration of etravirine and HIV protease inhibitors
Etravirine can be combined with most ritonavir-boosted HIV protease inhibitor regimens. Darunavir/ritonavir, lopinavir/ritonavir and saquinavir/ritonavir can be coadministered with etravirine because the added benefit of etravirine was confirmed in the DUET trial in which all patients received darunavir/ritonavir and comparable decreases in etravirine pharmacokinetics were observed. Country-specific recommendations exist for coadministration of etravirine with atazanavir/ ritonavir or fosamprenavir/ritonavir. In North America, coadministration of etravirine and atazanavir/ritonavir or fosamprenavir/ritonavir is not recommended because of the pharmacokinetic interactions and the lack of supporting clinical data for these specific combinations. In most of Europe, combination with atazanavir/ritonavir is allowed, pending confirmatory data in a clinical trial. Fosamprenavir/ritonavir is also allowed in most European countries but a dose adjustment for fosamprenavir (using the oral solution) is recommended when combined with etravirine. Assessing plasma concentrations of amprenavir, where available, might help guide dose selection. Combining etravirine with unboosted protease inhibitors, high-dose ritonavir or tipranavir/ ritonavir is not recommended.
Notably, rifabutin is not recommended in combination with etravirine and boosted HIV protease inhibitors in the United States because of the potential for significant decreases in etravirine exposure, but can be used with caution in most European countries. Rifabutin can be combined with etravirine in the absence of a boosted HIV protease inhibitor.
Potential for interactions of etravirine with newer antiretroviral classes
Enfuvirtide
Enfuvirtide is a peptide that prevents viral fusion with host cells by binding to gp41 [58] . As such, it can be expected to undergo catabolism rather than metabolism. In vitro data from human hepatic microsome studies show that enfuvirtide is not a substrate for any of the major CYP isoenzymes [58] . Use of enfuvirtide had no effect on etravirine AUC 12 h in the Phase III DUET trials [24] .
Maraviroc C-C chemokine receptor type-5 antagonists, vicriviroc and maraviroc, are primarily metabolized by CYP3A and are substrates for P-glycoprotein but do not affect hepatic drug metabolizing enzymes [59] [60] [61] .
To assess the clinical implications of combining etravirine 200 mg twice daily (Phase III formulation) or etravirine/darunavir/ritonavir (200/600/100 mg twice daily) with maraviroc (300 or 150 mg twice daily when combined), an open-label, crossover trial was conducted in 14 healthy volunteers [62] . Maraviroc did not affect etravirine (Table 1) , darunavir or ritonavir pharmacokinetics; however, when combined with etravirine, the AUC 12 h and C max of maraviroc were decreased by 53% and 60%, respectively, compared with maraviroc alone ( 
Raltegravir
Raltegravir is primarily metabolized by glucuronidation and does not appear to inhibit or induce CYP enzymes [63] . An open-label, three-period, fixed sequence study investigated the pharmacokinetic interactions between etravirine 200 mg once every 12 h (Phase III formulation) and raltegravir 400 mg once every 12 h in 20 healthy volunteers. Results from this trial showed no clinically relevant effect on etravirine exposure compared with sole administration of each agent (Table 1 ) and a modest (34%) decrease in raltegravir C min , whereas AUC 12 h , C max and T max were not altered to a clinically relevant extent (Table 2 ) [64] .
A recent case report described four HIV-infected patients who had low raltegravir trough concentrations while receiving coadministered etravirine. Of these patients, only one had a demonstrable decrease in raltegravir trough concentration caused by the introduction of etravirine. The clinical outcome in these patients was not described [65] . A larger cohort of HIV-infected patients receiving raltegravir and etravirine (n=22) found no statistically significant effect of etravirine on raltegravir plasma concentrations determined approximately 3 h and 12 h post-dose at weeks 4, 12 and 24 [66] .
Elvitegravir/ritonavir
Elvitegravir is a CYP3A substrate [67] . In clinical trials, elvitegravir is boosted with ritonavir or the novel pharmacoenhancer GS-9350. The potential for a drugdrug interaction between elvitegravir/ritonavir 150/100 mg once daily and etravirine 200 mg twice daily (Phase III formulation) was investigated in an open-label, crossover trial of 31 healthy volunteers [68] . Following coadministration, the pharmacokinetic parameters of etravirine (Table 1) , elvitegravir ( Table 2 ) and ritonavir were unaffected.
Recommendations for coadministration of etravirine with newer antiretroviral classes
As there is no interaction between etravirine and enfuvirtide when coadministered, no dose adjustments of either agent would be required. No dose adjustment for etravirine is necessary when coadministered with maraviroc. When combined with etravirine in the absence of potent CYP3A inhibitors (for example, without a boosted HIV protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily because of the reduction in maraviroc exposure. The local prescribing information of maraviroc should be consulted for the recommended dose of maraviroc when combined with etravirine in the presence of potent CYP3A inhibitors (for example, boosted HIV protease inhibitors).
Etravirine can be coadministered with raltegravir or elvitegravir/ritonavir without dose adjustments. The overall modest decrease in raltegravir C min does not require dose adjustment based on the efficacy demonstrated by raltegravir doses ranging from 100 to 600 mg twice daily in treatment-naive patients [69] and from 200 to 600 mg twice daily in treatment-experienced patients [70] . The interaction between elvitegravir boosted by GS-9350 and etravirine has not been evaluated.
Conclusions
The comprehensive research programme designed to assess how etravirine influences or is influenced by other antiretrovirals has shown that etravirine can be combined with all N(t)RTIs with no dose adjustments required for either drug and that, in line with current clinical practice, other NNRTIs should not be coadministered with etravirine It has also shown that etravirine can be combined with most ritonavir-boosted HIV protease inhibitors; however, coadministration with tipranavir/ritonavir is not recommended because of the decrease in etravirine exposure. Combinations of etravirine with unboosted HIV protease inhibitors are not recommended as protease inhibitor exposure might be significantly altered. Etravirine can be administered with the raltegravir or elvitegravir/ritonavir without dose adjustment of either drug and etravirine can also be administered with the enfuvirtide without dose adjustment of either drug. Regarding the C-C chemokine receptor type-5 antagonists, dose adjustments of maraviroc are required when coadministered with etravirine, depending on whether a boosted protease inhibitor or other potent CYP3A inhibitor is present in the regimen. In conclusion, etravirine has demonstrated the ability to be coadministered with a wide variety of antiretroviral agents.
